Helen Louise Collins, Chief Medical Officer: Enliven Therapeutics ELVN Sell · Filed 04/21

Trade details

Type: Insider sale
Amount: $117,314.46
Shares · price: 2,441 sh · $48.06 a share
Held after: 25,000 sh
Stock: Enliven Therapeutics ELVN
Person: Helen Louise CollinsChief Medical Officer
Trade date: 26/04/17
Filed: 26/04/21
Days to filing: 4 days

Sold 8.9% of holdings

Share of holding sold: 8.9%

Enliven Therapeutics trades, last 26 weeks

What else happened in Enliven Therapeutics around then

Filed or reported within 30 days of the trade day · 03/18~05/17

Helen Louise Collins's recent trades

Helen Louise CollinsChief Medical Officer
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$762.9K
15,000 sh
$762.9K
Filed 07/17
Traded 07/17
Helen Louise CollinsChief Medical Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$114K
2,599 sh
$114K
Filed 06/22
Traded 06/17
Helen Louise CollinsChief Medical Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$54.3K
1,268 sh
$54.3K
Filed 06/22
Traded 06/17
Helen Louise CollinsChief Medical Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$50.7K
1,133 sh
$50.7K
Filed 06/22
Traded 06/17
Helen Louise CollinsChief Medical Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$137.4K
3,475 sh
$137.4K
Filed 05/20
Traded 05/18

Helen Louise Collins, Chief Officer — sold $117.3K of Enliven Therapeutics ELVN · 8.9% of holdings · 10b5-1 plan | Whalegun